subscribeSubscribe
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion U.S. Patent

Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion U.S. Patent
GLOBENEWSWIRE
06 Sep 2022
Share Share
Sun Pharma presents clinical insights of ODOMZO and LEVULAN KERASTICK

Sun Pharma presents clinical insights of ODOMZO and LEVULAN KERASTICK
EXPRESS PHARMA
12 Jun 2020
Share Share
Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts

Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts
PRNEWSWIRE
10 Jun 2020
Share Share
Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union

Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union
BUSINESSWIRE
03 Mar 2020
Share Share
‘Groundbreaking’ new brain cancer treatment available

‘Groundbreaking’ new brain cancer treatment available
Anna Smith PHARMA TIMES
13 May 2019
Share Share
Alnylam shores up enthusiasm for givosiran with early dataset

Alnylam shores up enthusiasm for givosiran with early dataset
Amber Tong ENDPTS
07 Feb 2019
Share Share
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
Ben Fidler XCONOMY
16 Oct 2018
Share Share
Sun Pharma`s subsidiary files patent infringement suit against Biofrontera

Sun Pharma`s subsidiary files patent infringement suit against Biofrontera
Divya Rajagopal ECONOMIC TIMES
12 Jul 2018
Share Share
NICE backs use of dye for brain tumour removal

NICE backs use of dye for brain tumour removal
Selina McKee PHARMA TIMES
11 Jul 2018
Share Share
Biofrontera files for IPO to run skin cancer clinical trials

Biofrontera files for IPO to run skin cancer clinical trials
Nick P. Taylor FIERCE BIOTECH
15 Jan 2018
Share Share